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This historic article review addressing several articles, in-
cluding P. W. Wilson et al.’s seminal 1980 article on the
Framingham Offspring Study, clearly demonstrates how the
Framingham Heart Study was a true milestone in the
history of cardiology.
Prevalence of Coronary Heart Disease
in the Framingham Offspring Study:
Role of Lipoprotein Cholesterols
by P. W. Wilson, R. J. Garrison, W. P. Castelli,
M. Feinleib, P. M. McNamara, and W. B. Kannel (6)
ABSTRACT
Forty-three of 1,312 men aged 35 to 54 years in the Framing-
ham Offspring Study had clinically recognized coronary heart
disease at the initial examination. Twenty-six men in this
group had previously had a myocardial infarction. Of 1,296
women in the same age range, only 11 had coronary disease and
3 a prior myocardial infarction. The prevalence of coronary
heart disease in men was strongly associated with age, smoking,
high density lipoprotein (HDL), low density lipoprotein (LDL)
and total cholesterol using univariate analyses. When multivar-
iate logistic regression analysis was used, age, smoking and
HDL and LDL cholesterol retained their significant association
with coronary heart disease. The total cholesterol/HDL choles-
terol ratio was also strongly associated with coronary heart
disease in the multivariate analysis. It is concluded that both
HDL and LDL cholesterol are strongly and independently
associated with the prevalence of coronary heart disease, whereas
the level of very low density lipoprotein cholesterol makes no
statistically significant independent contribution.
Originally published in American Journal of Cardiology, October 1980.
Review
In the late 1940s, a longitudinal observational overview—
the Framingham Heart Study—was organized and funded
by grants from the National Heart Institute (1). This study
was launched after World War II, when the alarming
prevalence of atherosclerotic vascular disease was appreci-
ated, and its primary relation to sudden death, myocardial
infarction and stroke recognized. From this realization came
an understanding of the potential for the serious personal,
economic and political consequences of atherosclerotic ves-
sel disease (ASVD) and the identification of ASVD as a
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opments in their field.
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national concern. To better define the prevalence, demog-
raphy and correlates of atherosclerosis required a compre-
hensive epidemiologic survey of the disorder and associated
or causative factors. Initially, it was thought that a single
general etiology for atherosclerotic disease would be found;
it is now clear that atherosclerosis and its complications
must be considered as both polygenic and multifactorial.
In a recent article titled “Unlocking the Heart’s Secrets,”
U.S. News and World Report (Sept. 7, 1998) (2) declared,
“The Framingham Heart Study is one of the most cele-
brated works of epidemiology in the history of medicine.”
Dr. M. E. DeBakey commented, “It has set the model in
epidemiology. . . . It is truly one of the great studies of this
century.”
It is generally agreed that the Framingham Heart Study
has provided information critical to the recognition and
management of atherosclerosis and its secular causes and
complications. In the near future, new knowledge of the
polygenic background of these vascular disorders and their
fundamental biology, identification of “genetic” protection
against, or propensity for, those biologic mechanisms and
responses that underlie arterial wall pathology, and throm-
botic responses to injury will provide a further paradigm
shift in the understanding of atherosclerosis.
Regrettably, common use of terms from authoritative lay
dictionaries without regard for actual medical definitions
has irrevocably established the terms “prevention,” “prima-
ry,” and “secondary” in this field. “Prevention,” for example,
is defined in Webster (3) as follows: “1. To keep from
occurring, 2. to stop from doing something, 3. to interpose
a hindrance.” To “prevent,” therefore, is to stop something
by forestalling action and rendering it impossible. This
desired outcome—the elimination of atherosclerotic vascu-
lar disease by current strategies—is currently improbable in
all but a few individuals who are genetically fortunate. In
contrast, to “hinder” is to hold back by delaying or stopping
progress or action; this term is more appropriate for current
accomplishments. True prevention will require solution of
the second component of the problem—the genetic predis-
position or susceptibility to vascular disease or the protec-
tion against the influence of secular factors known and
unknown. Genetics govern cellular and system responses.
Some persons may have “healthy” endothelium, and others
may have a thrombotic overresponse. These opposite and
complex mechanisms are essential targets for future research
that might permit true prevention.
THE FRAMINGHAM HEART STUDY
For the first collection of community cohort information,
1,980 men and 2,421 women were enrolled between 1948
and 1951 (4). Historical data collected sought evidence for
prior coronary heart disease (CHD) and specifics regarding
blood pressure elevation, smoking habits and alcohol use
were also included. A physical examination was conducted
and an electrocardiogram obtained. Laboratory values, in-
cluding serum lipoprotein cholesterol levels, were obtained
by standardized methods, but values of high-density li-
poprotein cholesterol (HDL-C) were not measured in all
subjects. The resulting seminal article, “Factors of Risk in
the Development of Coronary Heart Disease: Six-Year
Follow-up Experience. The Framingham Heart Study” was
published in the Annals of Internal Medicine in 1961. From
this article, the concept of “risk factors” was elaborated upon
and the development of a cardiovascular risk profile
emerged (5–7).
The Framingham Offspring Study. The report, “Preva-
lence of Coronary Heart Disease in the Framingham
Offspring Study: Role of Lipoprotein Changes,” reproduced
in abstract form earlier in this article, first appeared in the
October 1980 issue of the American Journal of Cardiology (8).
The cohort subjects consisted of the original 1,980 men and
2,421 women entered in the Framingham Heart Study
between 1948 and 1951. The offspring subjects consisted of
1,719 men and 1,768 women—who were either genetic or
adoptive offspring, or spouses of offspring of the original
cohort. The HDL-C, an important variable not previously
measured in many of the cohort group, and body weight and
estimates of obesity were included. A greater proportion of
younger men and women were represented in the offspring
group. Of the men, 43 had clinically recognized CHD at
enrollment, as did 11 of the women. The crude rate of
clinical CHD (per 1,000) for the offspring slightly exceeded
that of the cohort—25 versus 18 for men and 7 versus 6 for
women. As in the cohort study, the prevalence of CHD was
strongly associated with age, gender, smoking, systolic
blood pressure and total cholesterol (T-C) and low-density
lipoprotein cholesterol (LDL-C) levels, thus validating the
prior conclusions. In addition, a decreased level of HDL-C,
especially in women, and an increased T-C/HDL-C ratio
were also found to be strongly associated with increased risk.
Interestingly, the level of very low-density lipoprotein cho-
lesterol (VLDL-C) did not prove to be an independent risk.
The finding of several risk factors in an individual subject
was of particular significance in regard to overall or total
individual risk for an adverse vascular event. The 12-year
incidence of CHD in the Framingham offspring was re-
ported in 1991 (9). Over the 12 years, 156 of the 1,663 men
and 55 of the 1,714 women developed clinical CHD. Once
again, CHD was significantly associated with age, gender,
LDL-C levels, lower HDL-C levels and number of ciga-
rettes smoked. Fasting glucose and LDL-C levels were
highly associated with CHD in men but were borderline in
women, whereas triglyceride and VLDL-C levels were not
significantly associated with CHD after adjustment for
HDL-C and blood glucose. Remarkably, a statistically
significant association between systolic blood pressure and
coronary artery disease (CAD) was not demonstrated in
either men or women. Hypertension control had increased,
cigarette smoking had declined during the 1970s and 1980s
and the potential for large reductions in blood cholesterol
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levels was evident. The longitudinal aspect of the study of
CHD events again underscored the importance of lipids and
fostered programs to optimize both T-C and LDL-C levels.
Epidemiology as a science basic to atherosclerosis and
CAD. Although most reports concerning the Framingham
Heart Study have appeared in general medical and epide-
miologic journals, Dr. William B. Kannel’s Bishop Lecture,
“Contribution of the Framingham Study to Preventive
Cardiology,” published in the Journal of the American College
of Cardiology in 1990 (10), amply justified the epidemiologic
approach to the study of such a multifactorial disorder.
Reliable, objective information was now available regarding
the incidence of cardiovascular disease and the importance
of risk factors in predicting the propensity for adverse
clinical events.
Influence. This series of seminal reports (4–10) resulted in
the establishment of the Lipid Research Clinic project (11)
and the National Cholesterol Education Program (12,13),
which have focused on the optimal management of athero-
sclerosis and CAD. The Framingham data have served
many nations and remain the bedrock of programs world-
wide. Unfortunately, control of lipids by diet alone has not
proven satisfactory in U.S. patients (14,15). This finding has
fostered the development of pharmaceuticals to effectively
and safely reduce T-C and LDL-C (16). Prior concern
regarding potential adverse clinical outcomes of lowered
T-C has not been substantiated (17). Randomized clinical
trials (RCTs) using drugs of the hepatic hydroxymethyl
glutaryl coenzyme A (HMG Co-A) reductase-inhibitor
class (“statins”) have shown significant lowering of T-C and
LDL-C to be associated with a striking reduction in CAD
events in men and women following acute myocardial
infarction (AMI) (18), men at greatly increased risk but
without prior AMI (19), men and women with normal T-C
levels post-AMI (20) and in a general population not at
increased risk (21). However, RCTs serve only to distribute
risk equally between enrolled test and control arms. Within
each arm, the subjects are far from homogeneous, with
individual risks ranging from negligible to inevitable. An
RCT will demonstrate only an “average” outcome and
whether any change between the means in placebo and
treated groups is not due to chance alone. This “average” is
due to a shift in the distribution of individual outcomes, and
it is not illogical to postulate that this shift must occur in
individuals within a cohort who are at greatest individual
risk. Hence, clinical trial data must be reassessed with care
to ensure that only those who can benefit receive treatment
and that resources are not expended by “treating” persons
who cannot benefit. Subpopulation analysis of risk is now
critical, if for no other reason than to minimize inclusion of
those at minimal risk for an adverse event.
The 27th Bethesda Conference of the American College
of Cardiology (22), co-chaired by Drs. Thomas S. Pearson
and Valentin Fuster, underscored the importance of
“matching the intensity of treatment with the hazard for
CAD events.” This principle is imperative because the cost
of general application of statin therapy for all subjects at any
level of risk would be prohibitive (23).
Dr. Peter Wilson has summarized the secular trends in
cardiac risk factor levels from the Framingham experience
(24). Mean systolic blood pressures were lower in the
second-generation subjects, and the proportion of persons
on blood pressure therapy increased in both sexes. Current
cigarette smoking decreased, and there was only a slight
increase in mean body mass levels. Whereas T-C and
LDL-C levels were lower in the Framingham offspring,
there was no significant difference between the cohort and
the offspring groups in triglyceride and HDL-C levels.
Although coronary death rates have declined greatly in the
Framingham Study results and in the U.S. since 1970, a
commensurate decrease in levels of coronary risk factors is
less apparent. A significant part of this decline is due not to
risk factor reduction but to treatment aimed at correcting a
specific feature in an individual patient, i.e., the use of
thrombolysis, coronary artery bypass graft (CABG) proce-
dures and, more recently, coronary angioplasty with or
without stent placement. Patients with any CHD events or
cardiac symptoms now undergo careful scrutiny, and when
secular risk factors are present (as they usually are), these
patients are targeted for prompt and effective treatment.
Again, the motivation of physicians and patients is strik-
ingly different after such a wake-up call.
Overall risk estimation. It is now incontrovertible that
blood pressure elevation, cigarette smoking, T-C levels and
their subfractions and the presence of diabetes or insulin
resistance combined with nonmodifiable factors of age and
gender can provide in numerical terms a probability for
CHD events over a follow-up interval of several years. A
scoring sheet that allows physicians to estimate CHD risk
has now been proposed (25). Although such estimates may
be less than precise, they serve as excellent guidelines and
may motivate patients at risk for CAD to adopt a healthy
lifestyle and, when necessary, to receive appropriate medi-
cation. If, indeed, the intensity of management is to relate to
the risk for coronary disease events, then a best numerical
estimate of risk is an essential starting place.
I believe that such a risk score should be included in the
chart of every patient; these scores would permit implemen-
tation of appropriate preventive strategies based on each
patient’s needs. For the future, it is reasonable to anticipate
major additions to enhance the precision and utility of the
Framingham risk estimate. Framingham fundamentally ob-
served patients in a free-living environment. The manage-
ment objective was, and is, primary prevention—namely, to
hinder the development of non- or preclinical atheroscle-
rotic disease and its complications. It is clear, however, that
the Framingham risk factors play an even more important
role in the management of existing coronary disease—
designated as secondary prevention—where the 10-year risk
is automatically doubled or quadrupled. To date, the most
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cost-effective application of risk factor management has
been in secondary prevention.
Accrual of carefully collected clinical detail about each
patient, as well as the selected use of more advanced
diagnostic techniques when required, can establish confi-
dence in the degree of risk estimation needed for clinical
decision making regarding treatment. Studies may include
stress testing (with or without radionucleide or echocardio-
graphic imaging), blood viscosity and white cell count,
coronary calcification score, perhaps fibrinogen and homo-
cysteine levels, and, in the future, identification of strong
genetic markers. Addition of these variables will refine the
accuracy of risk factor determinations and define more
exactly for which individuals within a certain population
specific therapy can be economically justified. Treatment
defined on the basis of lipoproteins alone can be grossly
misleading.
Impact of the Framingham Heart Study. Dr. Kannel’s
Bishop Lecture (10) summarized the contribution of the
Framingham Heart Study to preventive cardiology. The
association with frank diabetes or impaired glucose toler-
ance was greater in women but was also found to be highly
dependent on coexisting cardiovascular risk factors, includ-
ing lipid levels. Fibrinogen is another major and indepen-
dent atherogenic risk factor that may be involved in both
atherogenesis and thrombogenesis. The doubling of fibrin-
ogen levels from the lowest to the highest may double the
12-year rate of CHD events. The Framingham study found
a protective effect at low or moderate levels of exercise,
dispelling the previously held opinion that it was necessary
to exercise vigorously. Particularly in older individuals,
exercise at a moderate level seemed to reduce the adverse
CHD event rate by almost half over a 14-year interval.
Although weight gain was found to make a modest inde-
pendent contribution to CHD incidence, it, of course,
promotes all of the other major atherogenic risk factors,
including dyslipidemia, hypertension, impaired glucose tol-
erance, hyperglycemia and elevated fibrinogen; in addition,
it is associated with a more sedentary lifestyle. In Dr.
Kannel’s 1994 report (26), “Clinical Misconceptions Dis-
pelled by Epidemiological Research,” he proposed that,
even with current knowledge, a cardiovascular event must be
regarded as a medical failure rather than the first indication
of a treatment need. In most chronic congestive heart failure
(CHF) patients, the primary causes of CHF are hyperten-
sion and ischemic heart disease. The incidence of CHF
seems to be increasing, coincident with increased immediate
survival after AMI as a consequence of newer therapies,
including thrombolysis and primary angioplasty. The CHF
outcomes remain unsatisfactory in terms of morbidity and
mortality and now represent a great personal and economic
burden on the individual and on society. Because revascu-
larization does not decrease the incidence of AMI (27), lipid
lowering with this purpose in mind is an idea whose time for
testing has come. Epidemiologic studies have demonstrated
the relationship between peripheral arterial disease (PAD)
and cardiovascular disease. Not unexpectedly, CHD is the
most common immediate cause of death in PAD patients.
The same primary risk factors associated with CHD also
predict intermittent claudication and include systolic blood
pressure level, presence of diabetes, cigarette smoking,
elevated cholesterol and left ventricular hypertrophy. In
PAD, the most powerful risk factors are cigarette smoking
and diabetes.
Some, now mindful of the potentially dramatic changes
in management that have been suggested by new findings
on the fundamental processes of atherosclerosis, might
debate Dr. Kannell’s statement, “Epidemiology has emerged
as the basic science for preventive cardiology” (26). How-
ever, the significant progress that has been attained to date
in the management of vascular diseases is, nonetheless,
based on the insights provided by the Framingham Heart
Study investigators.
In spite of current trends toward, and increasing general
dependence on, drug therapy, as well as lack of confidence
in the U.S. in dietary approaches alone (19), recent data
from eastern Finland (28) suggest that programs of com-
munity education and the availability of low-fat food have
caused a significant reduction in lipoprotein risk factors.
This Finnish study underscores the importance of cost
considerations in the widespread application of all new
strategies. Therapy for all patients at any risk with statins is
cost prohibitive, even in the so-called developed countries.
CONCLUSIONS
The initiation of the Framingham Heart Study and the
offspring study were true milestones in the history of
cardiology—a conceptual leap forward. The resulting re-
ports have provided a fundamental approach to the man-
agement of atherosclerotic disease. We who are involved in
clinical care and clinical decision-making for individual
patients will forever remain in debt to the many outstanding
and dedicated scientists responsible for the purposeful
design, effective data collection and responsible interpreta-
tion of the secular factors that underlie atherosclerotic
vascular diseases.
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